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Abstract
Background: During the last years, several studies have reported the significant relationship between the production of
soluble HLA-G molecules (sHLA-G) by 48–72 hours early embryos and an increased implantation rate in IVF protocols. As
consequence, the detection of HLA-G modulation was suggested as a marker to identify the best embryos to be transferred.
On the opposite, no suitable markers are available for the oocyte selection.
Methodology/Principal Findings: The major finding of the present paper is that the release of ICAM-1 might be predictive
of oocyte maturation. The results obtained are confirmed using three independent methodologies, such as ELISA, Bio-Plex
assay and Western blotting. The sICAM-1 release is very high in immature oocytes, decrease in mature oocytes and become
even lower in in vitro fertilized embryos. No significant differences were observed in the levels of sICAM-1 release between
immature oocytes with different morphological characteristics. On the contrary, when the mature oocytes were subdivided
accordingly to morphological criteria, the mean sICAM-I levels in grade 1 oocytes were significantly decreased when
compared to grade 2 and 3 oocytes.
Conclusions/Significance: The reduction of the number of fertilized oocytes and transferred embryos represents the main
target of assisted reproductive medicine. We propose sICAM-1 as a biochemical marker for oocyte maturation and grading,
with a possible interesting rebound in assisted reproduction techniques.
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Introduction
Successful embryo formation and implantation are critical steps
during in vitro fertilization procedure. Unfortunately, approxi-
mately 10% of retrieved oocytes and fewer than 20% of
transferred embryos result in a successful delivery [1]. Analysis
of the embryo morphology in still one of the most common
approaches of selection in assisted reproduction, with the obvious
drawback of being to some extent subjective.
Accordingly, there is urgent need of biochemical markers
facilitating the prediction of successful oocyte fertilization and
implantation of the in vitro fertilized (IVF) human embryos. In this
respect, the only biochemical marker so far proposed for the
selection of the most promising embryo obtained by IVF is
represented by the release of in vitro cultured embryo (24-, 48- and
72-hours embryo) of soluble HLA-G (Histocompatibility Leuko-
cyte Antigen-G) molecules. This has been consistently reported by
several groups [2–7]. Using Enzyme-Linked Immunosorbent
Assay (ELISA) and Bio-plex approaches, these groups reported
that high expression of soluble HLA-G is associated with higher
pregnancy and implantation rates.
On the other hand the analysis of oocyte maturation might be of
great importance in predicting successful fertilization and embryo
development. As far as oocyte morphological criteria, several have
been claimed to correlate with outcome, including polar body
morphology [8]; cytoplasm appearance [9], and more recently
zona pellucida thickness, appearance and birefringence [10–12]
and the position or shape of the spindle [13]. Also in this case
biochemical markers helping in identifying oocytes completing in
vitro maturation would be very interesting in IVF approaches.
Markers of oocyte maturation are the presence of activated
mitochondria and the ability to mobilize and release calcium for
internal stores [14].
In this paper we analyze the release by oocytes and in vitro
fertilized human embryos of proteins involved in inflammation,
including several cytokines, chemokines and soluble Intercellular
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three independent methodologies, such as ELISA, Bio-Plex assay
[15,16], and Western blotting.
Results
Release of cytokines, chemokines and ICAM-1 by human
embryos
We first performed a preliminary screening of 11 embryos using
premixed multiplex beads of the Human 27-Plex Panel and the
ICAM-1 Bio-Plex kit, obtaining the following results. IL-1b, IL-2,
IL-4, IL-5, IL-10, IL-12 (P70), IL-15, IL-17, Basic FGF, G-CSF,
GM-CSF, IFN-c, MIP-1a, TNF-a were not present or undetect-
able in the analyzed supernatants. Presence of IL-1ra, IL-6, IL-7,
IL-8, IL-9, IL-13, Eotaxin, IP-10, MCP-1 (MCAF), MIP-1b,
PDGF-BB, RANTES, VEGF, ICAM-1 were detectable in 11, 1,
1, 10, 1, 1, 7, 1, 1, 1, 1, 1, 4, 11 embryos respectively. The only
proteins present in the supernatant of all the screened embryos
were ICAM-1 and IL-1ra. However, only ICAM-1 was expressed
at high levels. In additional experiments on other IVS embryos
(not included in this paper) we never found absence of ICAM-1
release, with the exception of few damaged embryos (data not
shown).
Quantization of sICAM-1: ELISA and Bio-Plex assay
In Figure 1 representative analysis is shown demonstrating that
levels of ICAM-1 standards are detectable following both ELISA
and the Bio-Plex assay. As expected, however, the Bio-Plex assay is
more sensitive than ELISA. This is of course important for analysis
of single cells, including oocytes. Accordingly, Bio-Plex analysis
was chosen for studies involving human oocytes and fertilized
embryos.
Comparison of sICAM-1 production in mature and
immature oocytes and in vitro fertilized embryos
Figure 2 reports a sharp difference in sICAM-1 levels among
immature and mature oocytes and fertilized embryos. The average
sICAM-1 production by immature (n=39) and mature (n=73)
oocytes was 6711.561502.4 and 29876103.7 pg/ml/24 hours
(mean6SD), respectively (Figure 2). This difference was very
reproducible and statistically significant (Student t Test,
p,0.0001). In addition, the levels of release of sICAM-1 levels
by mature oocytes and in vitro fertilized embryos (n=73),
1486.86164.2 pg/ml/24 hours, were also found to be significant-
ly different (Student t Test, p,0.0001) (Figure 2). Therefore, it
appears that the release of sICAM-1 has a clear tendency to
decrease from immature embryos, to mature embryos and to
fertilized embryos.
The presence of sICAM-1 molecules in oocytes culture
supernatants was also analyzed by western blotting. The results
obtained are shown in Figure 3. Standard positive ICAM-1
controls are shown in lanes ‘‘a’’ and ‘‘b’’. As clearly evident,
sICAM-1 is detectable both in mature (lane ‘‘d’’) and immature
(lane ‘‘e’’) oocyte supernatants. In addition, sICAM-1 is present in
mature oocytes in lower quantities in respect to immature oocytes,
fully in agreement with the Bio-Plex data shown in Figure 3. These
data were fully in agreement with ELISA assays (data not shown).
Production of sICAM-1 in immature and mature oocytes
Figure 4a reports the levels of sICAM-1 in immature oocytes at
different maturation stages (MI, Metaphase I; GV, germinal
vesicle; DEG, degenerated). The average released sICAM-1 was
5900 pg/ml/24 hours for MI oocytes, 6600 pg/ml/24 hours for
GV oocytes and 6600 pg/ml/24 hour for DEG oocytes. The
difference between sICAM-1 production by MI, GV and DEG
Figure 1. ELISA and Bio-Plex standard curves (white circles and black square respectively) have been obtained with 50 ml of ICAM-1
standard reagent at the concentrations of 0.25, 0.5, 1, 2, 4, 8 ng/ml or 0.0002, 0.00081, 0.0032, 0.0129, 0.0516, 0.20638, 0.82522,
3.3 ng/ml as indicated. FI: fluorescence intensity values. OD 450 nm: optic density at 450 nm wavelength.
doi:10.1371/journal.pone.0003970.g001
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p=NS) (Figure 3a).
Moreover, Figure 4b reports the analysis of ICAM-1 release in
mature oocytes subdivided in grade 1, 2 and 3, as reported in the
material and methods section. The average released sICAM-1 was
2804 pg/ml/24 hours for grade 1 oocytes, 2978 pg/ml/24 hours
for grade 2 oocytes and 2923 pg/ml/24 hours for grade 1 oocytes
(Figure 4b). Statistical analysis showed significant lower levels of
sICAM-1 in grade 1 oocyte supernatants in comparison to grade 2
(Student t Test, p=0.018) and grade 3 (p=0.02) oocyte
supernatants. Therefore, lower slCAM-1 levels in mature oocyte
are predictive for the best grade oocytes (Grade 1).
sICAM-1 levels and Embryo Grade
Figure 5 represents sICAM-1 levels in embryo culture
supernatants graded as reported in the Methods section. The
average levels of sICAM-1 were 1476.36187 pg/ml/24 hours in
the 29 Grade 1 embryos; 1522.46206 pg/ml/24 hours in the 13
of Grade 2; 14816116 pg/ml/24 hours in the 15 of Grade 3;
1461.96143.9 pg/ml/24 hours in the 16 Grade 4 and 5 embryos.
The differences between sICAM-1 production by Grade 1, 2, 3,
4 and 5 embryos were not statistically significant (Student t Test,
p=NS).
sICAM-1 levels in oocyte supernatants and pregnancy
rate
Table 1 reports the sICAM-1 mean levels observed in mature
oocyte and embryo culture supernatants subdivided for implan-
tation and pregnancy outcome.
There were no statistical differences (Student t Test, p=NS) in
sICAM-1 levels observed in the supernatant of oocytes and
embryo with a negative or positive implantation and pregnancy
rate (Table 1).
The relationship between oocyte grade (Figure 4b) and
implantation/pregnancy rate was not investigated, since we were
not able to associate the pregnancy event to a specific embryo. In
fact, our IVF protocol, in order to achieve the highest probability
of pregnancy and meet law restrictions [17], allows the transfer of
three embryos that could originate from different grade oocytes.
Comparison of sICAM-1 and sHLA-G levels in
supernatants of oocytes using Bio-plex technology
Since the release of soluble HLA-G (sHLA-G) molecules by in
vitro fertilized embryos seems to help the morphological
characterization in the selection of the most promising embryo
obtained by IVF and has been proposed as a possible candidate
marker for oocyte maturation [17] we compared the release of
these two proteins in our samples. Representative analyses are
shown in Figure 6, which clearly indicate that in human oocytes
the release of sICAM-1 is far more efficient that release of sHLA-G
molecules. In general, the release of sHLA-G molecules is very low
in most of the oocytes employed. On the contrary, confident
results are obtained studying sICAM-1, due to the high release of
this protein by human oocytes.
Discussion
The reduction of the number of fertilized oocytes and
transferred embryos represents the main target of assisted
reproductive medicine. During the last years, several studies have
Figure 2. sICAM-1 release in immature oocytes (black box)
compared to mature (white box) oocytes and to in vitro
fertilized embryo (grey box). Oocytes were individually cultured in a
4-well culture dish as reported in the methods section. Following the
maturation period 250 ml of supernatants were collected from each
culture system and stored at 220uC until being tested for the presence
released proteins. Mature and immature oocytes were identified, one by
one, evaluating the presence or absence of the first polar body. In vitro
fertilized embryos were individually cultured in 4-well culture dishes
and 250 ml of supernatants collected from each embryo culture and
stored at 220uC until being tested for the presence of released
proteins. * Student t Test.
doi:10.1371/journal.pone.0003970.g002
Figure 3. Western blotting analysis. The anti-ICAM-1 MoAb was
used for the detection. a: standard positive control loaded at 8000 pg;
b: plasma sample loaded at 10000 pg, accordingly to ELISA detection; c:
medium negative control; d: mature oocyte supernatant loaded at
35 pg accordingly to ELISA detection; e: immature oocyte supernatant
loaded at 100 pg accordingly to ELISA detection; M: protein ladder.
doi:10.1371/journal.pone.0003970.g003
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sHLA-G molecules by 48–72 hours early embryos and an
increased implantation rate in IVF protocols [18]. As conse-
quence, the detection of HLA-G modulation was suggested as a
marker to identify the best embryos to be transferred. On the
opposite, no suitable markers are available for the oocyte selection.
The major finding of this paper is the detection, by a reliable
technique, of soluble ICAM-1 molecules in the culture superna-
tants of human in vitro maturated oocytes and in vitro fertilized
embryos. The data obtained showed a significant difference in
sICAM-1 levels between immature and mature oocytes with
significant higher amounts of sICAM-1 in the oocytes that failed to
maturate. When the immature oocytes were morphologically
classified in metaphase I, germinal vesicle and degenerated
phenotypes we observed similar levels of sICAM-1 in the three
groups. On the contrary, the mature oocytes subdivided into grade
1, 2 and 3 presented lower s-ICAM-1 levels in grade 1 group.
Therefore, these results propose sICAM-1 levels as predictive for
oocyte maturation and quality. Biochemical markers of the oocyte
maturation are very important, due to the fact that (a) during in
vitro oocyte maturation no ore than 50% of the oocytes isolated
from a single woman reach grade 1 (Table 2); (b) only these
oocytes are routinely considered for IVF. In addition, we like to
point out that in some countries no embryo selection is allowed,
only a limited number of oocytes are fertilized and all of the
obtained embryos must be implanted [19].
The culture supernatants of early embryos showed sICAM-1
levels lower in comparison to both mature and immature oocytes.
Interestingly no significant differences were observed in sICAM-1
concentrations in the culture supernatants of early embryos
subdivided into grades. These results underline the importance
of sICAM-1 as a marker of the oocyte maturation process but not
of the early embryos development.
This is the first report showing release of sICAM-1 in human
oocytes and IVF human embryo. However the expression of
ICAM-1 in human embryos is not surprising, when considering
the implantation phase. In this context, ICAM-1 has been already
presented as a protein involved in inflammation. In fact ICAM-1
knock-out mice do not develop inflammation and have less
Figure 4. sICAM-1 levels in culture supernatants from imma-
ture (a) and mature oocytes (b). Immature oocytes were analysed
individually for morphological characteristics to differentiate them as
Metaphase I (MI), germinal vescicle (GV) and degenerated (DEG). (a).
Mature oocytes were subdivided on the basis of the first polar body and
cytoplasm characteristic in Grade 1, 2 and 3 (b). Preparation of oocyte
supernatants was performed as described in the legend to Figure 2. *
Student t Test.
doi:10.1371/journal.pone.0003970.g004
Figure 5. sICAM-1 levels in embryo culture supernatants subdivided into grades as reported in the Methods section.
doi:10.1371/journal.pone.0003970.g005
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associated with different diseases as infarct, biliary atresia, multiple
sclerosis, obesity [21–24]. When the sICAM-1 levels are compared
to sHLA-G, a soluble molecule involved in embryo implantation
[3], sICAM-1 showed higher levels in oocyte supernatants than
sHLA-G. These two molecules are both secreted by human
oocytes but with a more efficient release of sICAM-1 than of
sHLA-G molecules. In general, the release of sHLA-G molecules is
very low in most of the oocytes employed. On the contrary,
confident results are obtained studying sICAM-1, due to the high
release of this protein by human oocytes.
The results obtained are confirmed using three independent
methodologies, such as ELISA, Bio-Plex assay and Western
blotting. Therefore, we propose this biochemical marker to be
tightly linked to oocyte maturation. This finding is novel and, in
our opinion, very important in the field of the selection of oocytes
to be fertilized.
As known, the oocytes obtained under ovarian stimulation
present a variable competence and although molecular approach-
es have been proposed [25,26], the selection is still performed on
morphological characteristics such as ploidy and chromosome/
chromatin status. Since maturation of oocytes is so important for
in vitro fertilization approaches, we suggest sICAM-1 to be a
marker for testing different culture mediums under development
by several laboratories to the aim to obtain optimal in vitro oocyte
maturation.
In conclusion, our data encourage further studies from different




The oocytes employed in this study were obtained from
regularly cycling patients attending the Biogenesi Reproductive
Medicine Centre of Monza, Italy, for an Assisted Reproduction
Technique with In Vitro Maturation Protocol (IVM). Couples
included in the trial had an indication to IVF procedure because of
infertility due to male factor, tubal factor, stage I/II endometriosis,
polycystic ovarian syndrome (PCO) or unexplained cause. All the
women included had regular cycles of 26–35 days. A written
informed consensus was obtained from all participating couples.
We considered just one cycle per couple, and after maturation
process we used from one to three oocytes according to the Italian
Law 40 on IVF. Following these criteria, 42 women were recruited
for the study. Women characteristics are reported in Table 2.
Oocyte recovery was performed by means of transvaginal
ultrasonound–guided follicle aspiration, using a single lumen
aspiration needle (Gynetics cod. 4551-E2 Ø17- gauce 35 cm)
connected to a vacuum pump (Craft Pump pressure 80–
90 mmHg). The retrieved oocytes were surrounded by granulosa
cells forming a structure known as the cumulus ophorus complex
(COC). The COCs were washed with prewarmed Flushing
Medium with heparin (Medi-Cult product n. 10760125, Den-
mark).
The COCs, that for easiness we will define oocytes, were
detected under a stereomicroscope, examined and classified on the
basis of their morphology. Oocytes with signs of mechanical
damage or atresia were discarded.
Immature oocytes were individually cultured in a 4-well culture
dish with 0,5 ml of IVM Medium (vial 2 of IVM system medium;
Medicult no. 82214010, Denmark) supplemented with rec–FSH
0,075 IU/ml (Serono, Italy), hCG 0,1 IU/ml (Serono, Italy) and
10% Serum Protein Substitute (SPS no. 3010– Sage Media- USA)
for other 30 hrs.
Table 1. sICAM-1 release, implantation outcome and pregnancy outcome.
Implantation outcome Pregnancy outcome
positive negative positive negative
frequency (n) 7 35 4 38
sICAM-1 oocytes (pg/ml) 2865.46107.7 2856.96520 2858.46117.6 2860.76403.1
sICAM-1 embryos (pg/ml) 1424.16142.5 1493.86170.7 1463.56127.5 1483.96171.2
doi:10.1371/journal.pone.0003970.t001
Figure 6. Comparison of levels of sICAM-1 (black boxes) and
sHLA-G (white boxes) in supernatants of representative
oocytes. For sHLA-G detection, covalent coupling of the anti-sHLAG
antibodies to the carboxylated polystyrene microspheres (Bio-Rad,
Hercules, CA, USA) was performed using the Bio-Plex amine coupling kit
(Bio-Rad, Hercules, CA, USA). Bio-Plex assay was performed as elsewhere
reported [2].
doi:10.1371/journal.pone.0003970.g006
Table 2. Details of the in vitro maturation procedure.
Women (n=42)
Age (years) (mean6SD) 3563
Number of recovered oocytes per woman (mean6SD) 761
Mature oocytes per woman (%) 20–50
doi:10.1371/journal.pone.0003970.t002
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collected from each culture system containing a single oocyte and
stored at 220uC until being tested for the presence released
proteins.
The oocytes were then classified, one by one, evaluating the
presence of the first polar body to confirm Metaphase II stage and
their morphological characteristics.
Immature oocytes were classified as Metaphase I (MI), germinal
vesicle (GV) and degenerated (DEG) whereas mature oocytes were
classified on the first polar body and cytoplasm characteristics in
Grade1: homogenous cytoplasm and round polar body; Grade 2:
oocyte with variations in color or cytoplasm granularity and/or
presence of inclusions, vacuoles or retractable bodies, but a round
polar body: Grade 3: oocyte with variation in color or cytoplasm
granularity and/or presence of inclusions, vacuoles or retractable
bodies with a fragmented polar body.
Embryos were graded accordingly to cleavage (cell number) and
cytoplasmic fragmentation. Embryos were graded as follows on
Day 3: Grade 1, blastomeres have equal size and no cytoplasmic
fragmentation; Grade 2, blastomeres have equal size and minor
cytoplasmic fragmentation involving ,10% of the embryo; Grade
3, blastomeres have unequal size and fragmentation involving 10–
20% of the embryo; Grade 4, blastomeres have equal or unequal
size, and moderate to significant cytoplasmic fragmentation
covering 20–50% of the embryo; and Grade 5, few blastomeres
and severe fragmentation covering $50% of the embryo [17].
Measurement of sICAM-1 levels by enzyme-
immunosorbent assay (ELISA)
sICAM-1 concentrations were analyzed in triplicate on 1:2
diluted oocyte culture supernatants by the commercially available
sICAM-1 kit (Diaclone, Besancon, FR) with a detection limit of
0.25 ng/ml.
Western blotting
The presence of sICAM-1 molecules in oocyte culture
supernatants was analyzed by Western Blot. Briefly, concentrated
and albumin depleted (Enchant Life Science kit, Pall Corporation,
MI, US) oocyte culture supernatants were loaded on 8% SDS-
polyacrylamide gel, electrophoresed at 80 V for 2 hours and
blotted onto PVDF membrane (Immobilon-P Millipore, Billerica,
MA, US) by electrotransfer at 100 V for 45 minutes in 25 mM
Tris Buffer, 190 mM Glycine, 2% SDS and 20% (V/V) Methanol.
Blocking was carried out with 5% nonfat dry milk, Tris 100 mM
pH 7.5, NaCl 150 mM over night at 4uC. After two washes, the
membrane was incubated with monoclonal mouse-anti-human
ICAM-1 (10 mg/ml) (Genzyme, MA, USA) for 3 hours at room
temperature with gentle shaking. The sICAM-1 molecules were
detected using Protein-G HRP (BioRad, Hercules, CA, US) at
dilution of 1:5000 in 10 mM Tris pH 8.0, 150 mM NaCl, 0.1%
Tween 20. Reactions were developed by chemiluminescence with
SuperSignal enhanced chemiluminescence kit (Super Signal West
Pico system, Pierce, Rockford, IL, US) and captured by
Chemiluminescence Imaging Geliance 600 (PerkinElmer, CT,
USA). The ELISA standard (sICAM-1 kit (Diaclone, Besancon,
FR)) and a plasma sample were used as positive control, the
culture medium alone as negative control. The molecular weights
were determined with the BenchMark (Invitrogen, CA, US) pre-
stained protein ladder (range 10–200 kD). Densitometric analysis
was performed with the Gene Tools software (PerkinElmer, CT,
USA).
Cyto/chemokines and ICAM-1 profiles
Cytokines and chemokines presence were measured in embryo
culture supernatants by Bio-Plex cytokine assay (Bio-Rad Labo-
ratories, Hercules, CA) [15,16] described by the manufacturer.
The Bio-Plex cytokine assay is designed for the multiplexed
quantitative measurement of multiple cytokines in a single well
using as little as 50 ml of sample. In our experiments, we used the
premixed multiplex beads of the and Bio-Plex Human Cytokine
singleplex Assay ICAM-1 (Bio-Rad, Cat. no. XF0-000003N) and
Bio-Plex human cytokine Human 27-Plex Panel (Bio-Rad, Cat.
no. 171-A11127) which included twenty-seven cytokines [IL-1b,
IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (P70),
IL-13, IL-15, IL-17, Basic FGF, Eotaxin, G-CSF, GM-CSF, IFN-
c, IP-10, MCP-1 (MCAF), MIP-1a, MIP-1b, PDGF-BB,
RANTES, TNF-a, VEGF]. Briefly, 50 ml of cytokine/chemokine
and ICAM-1 standards or samples (supernatants from IVF human
embryos) were incubated with 50 ml of anti-cytokine/chemikine/
ICAM-1 conjugated beads in 96-well filter plates for 30 min at
room temperature with shaking. Plates were then washed by
vacuum filtration three times with 100 ml of Bio-Plex wash buffer,
25 ml of diluted detection antibody were added, and plates were
incubated for 30 min at room temperature with shaking. After
three filter washes, 50 ml of streptavidin-phycoerythrin was added,
and the plates were incubated for 10 min at room temperature
with shaking. Finally, plates were washed by vacuum filtration
three times, beads were suspended in Bio-Plex assay buffer, and
samples were analyzed on a Bio-Rad 96-well plate reader using the
Bio-Plex Suspension Array System and Bio-Plex Manager software
(Bio-Rad Laboratories, Hercules, CA).
Statistical analysis
Statistical analysis was conducted using the Stat View software
package (SAS Institute Inc, Cary, NC, US). The data were
analyzed by the Student t test for unpaired samples. Statistical
significance was assumed for p,0.05 (two tailed).
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